Skip to main content

Jersey Campaign Highlights How Cannabis Has Gone Mainstream In Germany

One area of society that cuts across political lines and socioeconomic backgrounds is sports. People from all walks of life love sports, with football (soccer) being the most popular sport around the world. Football is especially popular in Europe where hundreds of millions of fans are located.

With that in mind, it was a very big deal when the “Endlich” special jersey campaign was recently launched by SC Paderborn 07, Four 20 Pharma, and the Sanity Group, with part of the campaign involving pro-cannabis messaging being prominently placed at a recent football match.

Sport-Club Paderborn 07 e.V., commonly known as SC Paderborn 07 or SC Paderborn, is a German association football club based in Paderborn, North Rhine-Westphalia.

“Whether it’s the 2nd Bundesliga, Bundesliga or international football: special jerseys have become established and are often a real collector’s item for fans of the respective teams. They are usually issued for a special occasion such as a Champions League game. But sometimes they also have a much more serious background – as with the “Endlich” special jersey campaign by SC Paderborn 07, Four 20 Pharma GmbH (Four 20 Pharma) and the Sanity Group.” Four 20 Pharma GmbH stated about the effort.

“The jersey, which is all green with white accents and in which the SC Paderborn 07 team played against Jahn Regensburg, aims to draw attention to the issue of medicinal cannabis and counteract possible stigmatization and prejudice. There were also a variety of activities in and around the stadium – for example information stands and flyers on the seats.” the company also stated.

Below is footage from the match:

“The SCP07 team came onto the pitch dressed entirely in green and with a striking “Endlich” lettering and presented the jersey to the fans. During halftime, the special jerseys were then distributed using a “jersey cannon”. The oversized, inflatable jersey in the “Endlich” design on the forecourt was also an eye-catcher and a popular photo motif.” Four 20 Pharma GmbH stated.

“The other offers from the Endlich initiative were more informative – for example, the interior interview before the game or the 15,000 flyers that were distributed throughout the stadium and conveyed facts about the topic of medicinal cannabis and drew attention to a special Endlich Instagram filter. At information stands, visitors could also talk to medicinal cannabis experts, learn important facts and clarify questions.” they also stated.

Such a powerful message in such a mainstream setting is a big deal by every measure. Putting pro-cannabis messaging on such a grand stage no doubt reached parts of society that other pro-cannabis efforts simply cannot reach. It is an unparalleled effort that will reduce the stigma surrounding cannabis in Germany and beyond.

“After all, this is how we get into conversation with people who have not yet dealt with the topic or have not dealt with it sufficiently, or who are generally opposed to it. And that is exactly where we want to start: initiate a factual discussion, take the topic out of the dirty corner.” says Finn Hänsel, Managing Director & Founder of the Sanity Group.

“The feedback was overall positive, similar to the presentation of Four 20 Pharma as the main and jersey sponsor. We were happy to support this and with the joint special jersey campaign we helped to bring it even more into the public eye and to remove the taboo.” said Martin Hornberger, SCP 07 managing director.

The effort was also supported by TV presenter Matthias Killing (Sat.1 breakfast television), influencer Max Büchsenschütz, and professional athlete and motocross rider Tristan Hanak, who all participated in the campaign.

EU Court Of Justice Approves Indoor Hemp Cultivation

Humans have cultivated hemp under the sun for centuries, making use of their hemp harvests in several ways from making rope to paper to textiles. In recent years, the hemp plant has become the focus of significant research aimed at developing medications and other therapies.

Additionally, consumable hemp products have risen in popularity and availability across the globe thanks to regulatory changes and product innovations. ‘Floral hemp’ or ‘cannabis light’ products are particularly popular on the European continent.

How hemp is cultivated has evolved in recent decades. While hemp is still cultivated in large fields under the sun, many cultivators are growing hemp indoors under artificial lighting and incorporating cutting-edge techniques. According to a recent decision by the European Union Court of Justice, indoor hemp cultivation using hydroponics is permitted. Per excerpts from reporting by EU News:

According to the EU Court of Justice, member states cannot ban hemp cultivation in indoor hydroponic systems. The only limitation is respect for public health, that is, compliance with the legal limit of THC not exceeding 0.2 per cent.

According to the Court’s findings, hydroponic cultivation increases agricultural productivity, develops technical progress, and ensures better use of inputs. In addition, it ensures the security of supply, as it is not subjected to direct weathering, and reasonable prices to the consumer. Not allowing hemp farmers to benefit from the CAP with this innovative technique would cause significant economic damage (taking into account that the criteria for receiving funding are strict and well-defined at the European level to avoid illicit cultivation).

Hemp policy in the European Union remains hazy, with many regulations either involving a lot of grey areas, or nation-level regulations conflicting with EU-level policies and regulations. The current situation creates a lot of uncertainty for entrepreneurs, investors, and consumers.

The European Union is not the only jurisdiction to struggle with modernizing its hemp policies and regulations. Every other continent is also struggling to create sensible hemp policies and regulations as the global hemp market continues to evolve.

Topical Cannabis Cream Mitigates Pruritus In Thai Clinical Trial

Pruritus is a medical term for ‘itching.’ While pruritus can develop for a multitude of reasons, it is fairly common among patients with chronic kidney disease. According to a June 2024 study, the worldwide prevalence of pruritus is 39.8%.

The number of people suffering from chronic kidney disease around the globe is roughly 800 million people according to a study from 2022, although it is unknown how many of those suffering patients also suffer from pruritus.

A team of researchers in Thailand recently conducted a clinical trial involving topical cannabis cream containing both CBD and THC, with the cream being used by chronic kidney disease patients experiencing pruritus. Below is more information about the results of the clinical trial via a news release from NORML:

Pathum Thani, Thailand: The topical application of a cream containing CBD and THC reduces itch severity in patients with chronic kidney disease (CKD)-associated pruritus, according to placebo-controlled clinical data published in the journal Kidney Medicine.

Investigators associated with Thammasat University in Thailand assessed the use of a cannabis-infused cream versus placebo in pruritus patients. Subjects were administered either the cream or the placebo for four weeks. Patients were assessed at baseline and at two weeks and four weeks.

Compared to the placebo group, kidney disease patients using the cannabis-infused cream experienced less itching and improved quality of life.

The study’s authors concluded: “This study demonstrated that a cannabis-containing cream might be an effective treatment for CKD-associated pruritus in hemodialysis patients with limited adverse side effects. Further studies with larger sample sizes and longer durations of follow-up are suggested to ensure the reliability of the results, especially regarding itch-related quality of life.”

Full text of the study, “Cannabis-containing cream for CKD-associated pruritus: A double-blind, placebo-controlled trial,” appears in Kidney Medicine.

CBD Dosing Mitigates Spondyloarthritis Pain In Brazilian Case Report

Spondyloarthritis, sometimes referred to as spondyloarthropathy, is an inflammatory arthritis condition that affects the patient’s spine. The main symptom of spondyloarthritis in most suffering patients involves low back pain.

According to a study from 2020, researchers estimated that as many as .5% to 2% of the world’s population suffers from spondyloarthritis to some degree. Common treatments for the condition depend on the severity of spondyloarthritis in the patient.

Researchers in Brazil recently published findings for a case report involving cannabidiol (CBD) and spondyloarthritis. Below is more information about the study and its results via a news release from NORML:

São José do Rio Preto, Brazil: The daily administration of plant-derived CBD oil is associated with reduced spondyloarthritis-related pain and increased physical activity, according to a case report published in the journal Cureus.

A Brazilian researcher documented improvements in a 72-year-old male patient with neuropathic pain from spondyloarthritis, a chronic inflammatory disease that predominantly affects the spinal column. The patient suffered from chronic pain, numbness, diminished muscle strength, and limited movement due to his condition.

Treatment with CBD oil resulted in initial improvements within 20 days. These improvements became more pronounced over time. “After 90 days of treatment, the patient reported the absence of pain, the return of physical activity (walking and swimming), and the suspension of the use of analgesics. Muscle strength increased considerably and tremors in the left arm had diminished by 90 percent.”

The study’s author concluded, “Based on this result and considering scientific evidence of the effectiveness of CBD in the treatment of patients with chronic pain due to different illnesses, this therapeutic option may be beneficial to such patients when conventional medicinal treatment is unsatisfactory.”

Full text of the study, “Cannabidiol for the treatment of spondyloarthritis-related pain: A case report,” appears in CureusAdditional information on cannabinoids and pain management is available from NORML’s publicationClinical Applications for Cannabis and Cannabinoids.

CBD Skincare Market Expected To Experience Tremendous Growth

The overall cannabidiol (CBD) industry has experienced significant growth in recent years due to regulatory reforms and increased demand by consumers and patients. One sector that is witnessing the most growth is the CBD skincare market, which is projected to expand considerably in the coming years.

According to a recent market analysis by Allied Market Research, the global CBD skincare market is projected to reach $8.9 billion in value by 2033, a CAGR of 19.5%. The same market analysis estimates that the CBD skincare market was valued at $1.5 billion in 2023.

“Continuous innovation and new product launches by major skincare brands are attracting consumers and expanding the market. The influence of social media and celebrity endorsements is further enhancing market growth.” the researchers stated.

“Moreover, the increased availability of CBD skincare products through various retail channels, including online stores, specialty beauty shops, and health stores, is facilitating market expansion.” the researchers also stated.

A separate recent market analysis by SNS Insider also projects that the CBD skincare market will experience tremendous growth in the near future. According to SNS Insider, the CBD skincare market will be worth a projected $22.19 billion by 2032, a CAGR of 28.7%.

“Industry reports suggest that CBD skincare products are going to move upward, as growing awareness regarding the anti-inflammatory and antioxidant effects of CBD is entering as one of the largest most sought-after ingredients in modern skincare routines.” SNS Insider stated about the CBD skincare market. The market researchers also determined the following:

  • In 2023, the oils segment accounted for over 38.8 % of the total market share in the CBD skincare market
  • The segment of department stores had the highest share, above 29.0% in 2023
  • Hemp-based products topped the market with over 63.5% share in the year 2023
  • North America was established as a market leader in the CBD skincare product market in 2023

Additionally, according to a recent analysis by Research and Markets, the CBD nutraceuticals market will be worth an estimated $29.1 billion by 2030. The market analysis estimates that the CBD nutraceuticals market will be worth $9.7 billion in 2024.

Spain’s Ministry Of Health Publishes Medical Cannabis Draft Royal Decree

The road to properly regulated medical cannabis in Spain has been long and full of twists and turns. However, the effort to bring Spain’s medical cannabis policies into the modern age passed a major milestone with the nation’s Ministry of Health publishing a draft royal decree focused on medical cannabis.

“After three years of delays, Spain’s Ministry of Health published on Monday 30 September the draft royal decree to allow the prescription of cannabis preparations, a text that will now be submitted for hearing and information before its final approval.” reported Sur in its domestic coverage.

“The draft establishes broad restrictions on the medical use of cannabis and specifies very specifically the pathologies for which it can be used: multiple sclerosis (stiffness and muscle spasms associated with the condition); severe forms of refractory epilepsy (certain types of epilepsy that do not respond to conventional treatments); nausea and vomiting caused by chemotherapy; and refractory chronic pain (persistent pain that is not relieved by the usual treatments). In all these cases, experts believe that there is “scientific evidence” of the benefits of medical cannabis.” the media outlet also reported.

Back in February 2024, Spain started the process of crafting the draft royal decree that was recently published. As we reported at the time, before a royal decree is officially issued, the public is afforded the opportunity to provide input, with Spain’s government having previously set up an email address dedicated to receiving such input (normativa.aemps@aemps.es).

“The Ministry addresses this regulation based on the conclusions of the Subcommittee of the Congress of Deputies for the analysis of experiences with the regulation of cannabis for medicinal use, which called on the Spanish Agency for Medicines and Health Products to prepare a roadmap to approve the regulation.” Spain’s government stated in a press release (translated from Spanish to English) at the time.

“The proposed regulation guarantees the quality of the products and the safety of patients, enabling the legal avenues available to have therapeutic compounds based on standardized cannabis preparations that have shown evidence in relieving pain and the suffering of patients, considering the oral administration of these compounds as it is the most appropriate in terms of therapeutic effectiveness and safety for patients.” the government’s press release stated.

“This regulation is designed to evolve dynamically, allowing new elements to be incorporated as more information and the experience of the therapeutic cannabis program becomes available. In addition, it will contribute to generating more and better evidence on the use of cannabinoids for therapeutic purposes.” Spain’s government also stated.

Despite the lack of proper regulations in Spain, the nation’s cannabis industry is thriving, albeit not within a regulated system. Suffering patients deserve to have safe access to safe medical cannabis therapies, and entrepreneurs and investors deserve to operate in a business environment that is built on a strong foundation of certainty.

CBD Nutraceuticals Market Projected To Be Worth $29.1 Billion By 2030

The emerging cannabidiol (CBD) nutraceuticals sector is expected to experience tremendous growth through the remainder of this decade, with a recent report by Research and Markets projecting that the CBD nutraceuticals market alone will be worth an estimated $29.1 billion by 2030. The market analysis estimates that the CBD nutraceuticals market is worth $9.7 billion in 2024.

“Worldwide, the market for CBD Nutraceuticals is poised to record an above-average growth over the analysis period, the crucial reasons for which are the increase in demand for plant-based foods, growing awareness concerning benefits of CBD nutraceuticals, innovative products in the pipeline and CBD nutraceuticals in capsule & softgel forms undergoing further advancements.” the researchers stated in their analysis.

“North America represents the primary global market for CBD Nutraceuticals, the reasons for which include introduction of the 2018 Farm Bill that legalized hemp cultivation and processing of hemp-derived products, demand from consumers after getting to know the benefits of CBD-based Nutraceuticals, major companies active in the region and a significant rise in geriatric population.” Research and Markets stated.

“Asia-Pacific, though, is anticipated to be the fastest growing global region for CBD Nutraceuticals, factors for which comprise entry of leading global players, an increase in lifestyle-associated diseases & other health disorders and greater knowledge pertaining to healthier eating routines.” the market researchers also stated.

“CBD Oils account for the largest share, as they have great versatility in being used in a range of applications, such as capsules, tinctures and cosmetics. However, the global demand for CBD Isolates is likely to maintain the fastest growth, since these are considered to offer high purity, making them ideal as CBD formulations in products that need exact concentrations of CBD.” the researchers stated about subsectors of the market.

“A high demand has been evident for CBD Tinctures, since they widely utilized in treating insomnia, cancer cell growth, seizures, anxiety, depression and chronic pain, as well as hyperglycemia, muscle spasms, psychosis and bone degeneration. However, the demand for CBD Capsules & Softgels is expected to exhibit the fastest growth over the analysis period, since they are more convenient to consume and are also travel-friendly.” the researchers concluded.

A previous market analysis conducted by Market Research Future estimated that the global CBD industry was worth $18.43 billion in 2023 and that the market would reach a projected $59.43 billion by 2030.

UK Researchers Find CBD Mitigates Symptoms In High Risk Psychosis Patients

For many years, cannabis-based research was either outright prohibited in many parts of the world, or at the very least greatly hindered. Meanwhile, a false narrative was pushed by mainstream media and cannabis opponents that cannabis was ‘bad for the human brain in every instance, no exceptions.’

Of course, the truth is that as researchers continue to explore and unlock the wellness benefits of cannabinoids, we are learning that the cannabis plant can be effective at providing relief to suffering patients for a wide array of conditions, including mental health conditions.

A team of researchers recently conducted a clinical trial in the United Kingdom that explored the relationship between cannabidiol (CBD) and symptoms in patients with a high risk of psychosis. Below is more information about it via a news release from NORML:

London, United Kingdom: The daily use of cannabidiol reduces symptom severity in patients at clinically high risk of suffering from psychosis, according to placebo-controlled clinical trial data published in the journal World Psychiatry.

Thirty-one patients completed the study. Subjects received 600 mg of CBD or a placebo daily for three weeks. None of the participants received any prescription medications during the trial. Patients were assessed at baseline, at seven days, and at 21 days.

Compared to the placebo group, those who received CBD had lower total CAARMS (Comprehensive Assessment of At‐Risk Mental States) scores following treatment. CBD dosing was associated with a “reduction in the severity of CHR [clinically high risk] symptoms and the distress associated with psychotic experiences,” investigators reported.

The study’s authors concluded: “Short‐term treatment with CBD can ameliorate the symptoms of CHR state for psychosis and is well tolerated. These results highlight the potential of CBD as a novel treatment for psychosis, and the need for large‐scale efficacy studies to further evaluate its clinical utility.”

Separate studies have demonstrated that the use of CBD reduces psychotic symptoms and the use of antipsychotic medications in patients with schizophrenia.

Full text of the study, “Effects of cannabidiol on symptoms in people at clinical; high risk of psychosis,” appears in World Psychiatry.

Germany’s Agriculture Ministry Approves Historic Hemp Measure

Germany recently approved a draft law previously presented by the Federal Minister of Food and Agriculture Cem Özdemir. The approved measure liberalizes industrial hemp in Germany and is intended to make it easier to cultivate industrial hemp and permit its use.

As part of the measure, the ‘abuse clause’ will be deleted and the indoor cultivation of industrial hemp will be expressly legal.

“Especially in times of climate crisis, we are removing obstacles from the path of farmers who want to try something new in their fields or in their halls. Industrial hemp offers our agriculture many opportunities: It contains hardly any THC, which causes highs, is undemanding, requires hardly any pesticides, fertilizers or water, improves soil and provides a habitat for insects.” Minister Özdemir stated.

“The harvest can be processed in a wide variety of ways, from food to textiles. The abuse clause criminalized actually innocent industrial hemp growers despite their best intentions. Now it is finally time to let the grass grow over it. And a lot of it, if possible, so that the innovative scene of industrial hemp growers and processors can continue to develop in Germany too.” Minister Özdemir also stated.

The German Cannabis Industry Association (BvCW) welcomed the central elements of the reform in its recent newsletter.

“Until now, even the theoretical possibility of a slight intoxication through the private consumption of large quantities of products has led to the entire value chain being punishable. This special German regulation is now being abolished.” BvCW stated about the recently approved measure.

“We are finally freed from these unnecessary hurdles. This is a major political step forward for industrial hemp and will contribute significantly to the growth of the industry.” Marijn Roersch van der Hoogte, Department Coordinator for industrial hemp at BvCW, stated.

“We are pleased about this important step and will actively support the further parliamentary process.” Jürgen Neumeyer, Managing Director of BvCW, commented.

BvCW pointed out in its coverage of the approved hemp measure the need for further hemp policy and regulatory changes in Germany, including raising the THC limit from 0.3 to 1.0% and providing funding and standardizing measurement methods for cannabinoid values.

“After the legalization of cannabis as a recreational drug, there is no longer any reason for many restrictions on the cultivation of industrial hemp. The Industrial Hemp Liberalization Act removes hurdles for hemp cultivation. In the parliamentary process, we will take a close look at whether the law is sufficient or whether it still needs to be improved. The potential of the plant as a supplier of oil and fiber is enormous. We should use it.” Karl Bär (The Greens) told BvCW.